The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...
During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...
Virginia Marie Kowalski “Ginny”: 75 years old of Fox Lake, IL, passed away peacefully on Thursday, January 15, 2026, ...
ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Prior to the 1970s, researchers widely believed cervical cancer was caused by the herpes simplex virus. That understanding ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Shares surged 30% Thursday after reporting 700% Anktiva revenue growth and securing Saudi FDA approvals for lung and bladder ...
Onlymyhealth on MSN
Cervical Cancer Awareness Month: HPV Explained Beyond Vaccine
Human Papillomavirus HPV infection causes almost all cases of cervical cancer Our expert explains what HPV is its causes ...
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback